Inventor · disambiguated record
Michael C. Myers
Also filed as: MYERS MICHAEL · MYERS MICHAEL C
18 granted patents·7 pending applications·295 citations·filing 1993–2024
93Inventor score
Files withBRISTOL MYERS SQUIBB CO17ELAN CORP PLC3UNIV NORTHWESTERN2FUISZ INTERNATIONAL LTD1QUOIN PHARMACEUTICALS INC1
Top patents by PatentIndex Score
25 records- 0191US10266578B2Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·9 cites·30 claims
- 0289US5370879AFormulations and their use in the treatment of neurological diseasesELAN CORP PLC·Filed 1993·Granted Dec 6, 1994·97 cites·27 claims
- 0388US10011594B24-hydroxy-3-(heteroaryl)pyridine-2-one APJ agonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jul 3, 2018·4 cites·30 claims
- 0485US5540938AFormulations and their use in the treatment of neurological diseasesELAN CORP PLC·Filed 1994·Granted Jul 30, 1996·72 cites·8 claims
- 0583US6090830AControlled release compositions and methods for the treatment of hyperlipidemiaFUISZ INTERNATIONAL LTD·Filed 1998·Granted Jul 18, 2000·76 cites·11 claims
- 0680US10106528B26-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonistsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Oct 23, 2018·3 cites·58 claims
- 0779US12097242B2Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 24, 2024·0 cites·26 claims
- 0878US12097241B2Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 24, 2024·0 cites·17 claims
- 0975US11390616B2Apelin receptor agonists and methods of useBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jul 19, 2022·1 cites·4 claims
- 1075US11364281B2Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Jun 21, 2022·0 cites·2 claims
- 1174US11185570B2Method of treating cardiovascular disease and heart failure with modified relaxin polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 30, 2021·0 cites·20 claims
- 1272US5580580AFormulations and their use in the treatment of neurological diseasesELAN CORP PLC·Filed 1995·Granted Dec 3, 1996·33 cites·8 claims
- 1370US12168655B2Apelin receptor agonists and methods of useBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Dec 17, 2024·0 cites·14 claims
- 1464US7329775B2Compounds and related methods for mutant p53 reactivationUNIV NORTHWESTERN·Filed 2004·Granted Feb 12, 2008·0 cites·7 claims
- 1564US2019263791A14-hydroxy-3-(heteroaryl)pyridine-2-one apj agonistsBRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 1660US2024417369A1Rxfp1 agonistsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1760US2024252465A1Combination treatment for netherton syndromeQUOIN PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1859US7829304B2Compounds and related methods for mutant p53 reactivationUNIV NORTHWESTERN·Filed 2008·Granted Nov 9, 2010·0 cites·7 claims
- 1958US2025011288A1Rxfp1 agonistsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2058US2025221966A1Rxfp1 agonistsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2157US2025268903A1Rxfp1 agonistsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2251US10590113B26-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 17, 2020·0 cites·10 claims
- 2351US2011207726A1Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin SUNIV PENNSYLVANIA·Filed 2009·Application pending·0 cites
- 2440US10392347B22,4-dihydroxy-nicotinamides as APJ agonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Aug 27, 2019·0 cites·10 claims
- 2539US10669261B2Heteroarylhydroxypyrimidinones as agonists of the APJ receptorBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jun 2, 2020·0 cites·17 claims
Join the waitlist — get patent alerts
Get an alert when Michael C. Myers files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →